Location History:
- Bartonsville, PA (US) (1997)
- Stroudsburg, PA (US) (1998 - 2011)
Company Filing History:
Years Active: 1997-2011
Title: The Innovations of Robert C. Huebner
Introduction
Robert C. Huebner is a notable inventor based in Stroudsburg, Pennsylvania. He has made significant contributions to the field of immunology, particularly through his work on recombinant lipidated proteins. With a total of 12 patents to his name, Huebner's innovations have the potential to impact vaccine development and treatment methodologies.
Latest Patents
One of Huebner's latest patents is titled "Recombinant lipidated PsaA protein, methods of preparation and use." This invention relates to recombinant lipidated PsaA proteins and the constructs from which these proteins can be expressed. The patent details how lipidation is achieved using a heterologous leader sequence derived from the ospA gene, which is joined in translational reading frame with the psaA structural gene. Furthermore, the invention provides methods for preparing lipidated PsaA proteins and their use in immunological compositions. It also includes vaccines that comprise immunogenic lipidated PsaA proteins and outlines methods for using these vaccines in the prevention and treatment of infections.
Career Highlights
Throughout his career, Robert C. Huebner has worked with esteemed organizations such as Connaught Laboratories Limited and the National Institutes of Health, a component of the U.S. Department of Health & Human Services. His work in these institutions has allowed him to advance his research and contribute to significant scientific advancements.
Collaborations
Huebner has collaborated with notable colleagues, including Robert S. Becker and Maryann B. Gray. These partnerships have likely enriched his research and expanded the impact of his inventions.
Conclusion
Robert C. Huebner's contributions to the field of immunology through his innovative patents demonstrate his commitment to advancing medical science. His work continues to pave the way for new vaccine technologies and treatment options.